The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients
This study is aimed to compare the difference of neutropenia with peripheral neuropathy condition, after administration of 3 hours and 24 hours Paclitaxel infusion in adjuvant therapy with PaclitaxelCarboplatin toward patient with ovarian carcinoma. The method that used was experimental research with samples randomized after consecutively recruited based on inclusive criteria. Before and every after chemotherapy, NCS was performed and differential count laboratories’ test and then analysed with Ttest and Chisquare test. The result showed that from three times administration of 3 hours PaclitaxelCarboplatin infusion group, the neutropenia condition after first up to third chemotherapy was 20 %, 30 %, 30 %, and the peripheral neuropathy condition was 30 %, 60 %, 50 % respectively. Meanwhile, in 24 hours PaclitaxelCarboplatin infusion group, the incident of neutropenia after first up to third chemotherapy was 40 %, 50 %, 40 %, and the incident of peripheral neuropathy was 20 %, 20 %, 20 % respectively. The statistic result was p > 0.05. Hence, there was no significant difference in neutropenia and peripheral neuropathy incident on two study group.
Benedet JL, Hacker NF, Ngan HYS. Staging classification and clinical practice guidelines of gynaecologic cancers: FIGO Committee on Gynecologic Oncology and IGCS Guidelines. Sec ed. Elsevier; 2003. p. 92-114.
Stirrat GM, Mills MS, Draycott TJ. Ovarian neoplasma: Obstetrics and Gynaecology. British. Churchill Livingstone; 2003. p. 308-317.
Aziz MF, Andrijono, Saifuddin AB. Buku Acuan Nasional Onkologi Ginekologi. Jakarta : Yayasan Bina Pustaka Sarwono Prawirohardjo; 2006.
Berek JS. Ovarian cancer: Novak’s Gynecology. Ch 32. Ed. Berek JS. Lippincott Williams and Wilkins; 2002.
Angioli R, Panici PB, Kavanagh JJ, Pecorelli S, et al. Chemotherapy for Gynecological neoplasms. New York: Maecel Dekker; 2004. p. 1 – 32.
Bristow RE, Karlan BY. Surgery for Ovarian Cancer. Oxon, U.K; 2006. p. 87 – 171.
Fraser M, Leung B, Thompson WE, Tsang B, et al. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reproductive biology and endocrinology 1: 66 – 79; 2003.
Chabner BA, Longo L. Cancer Chemotherapy and Biotherapy, Principles and Practice 4th ed. Philadelphia. Lippincott Williams and Wilkins. 2006.
Breathnach OS, Kasturi V, Kaye F, Herscher L, Georgiadis MS, Edison M, et al. Phase II Neoadjuvant Trial of Paclitaxel by 96-Hour Continuous Infusion (CIVI) in Combination With Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology [Internet]. Ovid Technologies (Wolters Kluwer Health); 2002 Jun;25(3):269–73. Available from: https://doi.org/10.1097/00000421-200206000-00013
Du Bois A. A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer. CancerSpectrum Knowledge Environment [Internet]. Oxford University Press (OUP); 2003 Sep 3;95(17):1320–9. Available from: https://doi.org/10.1093/jnci/djg036
Brighton D, Wood Miriam. The Royal Marsden Hospital Handbook of Cancer Chemotherapy.British. Elsevier Churchill Livingstone; 2005. p. 3-30.
Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecologic Oncology [Internet]. Elsevier BV; 2007 May;105(2):299–303. Available from: https://doi.org/10.1016/j.ygyno.2006.12.031
Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995 Jun;1(6):599-606.
Jennens R, Rischin D, Yuen K, Toner G, Millward M. Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel. Gynecologic Oncology [Internet]. Elsevier BV; 2003 Oct;91(1):190–3. Available from: https://doi.org/10.1016/s0090-8258(03)00459-1
Mielke S. Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer. Clinical Cancer Research [Internet]. American Association for Cancer Research (AACR); 2005 Jul 1;11(13):4843–50. Available from: https://doi.org/10.1158/1078-0432.ccr-05-0298
Lee JJ, Swain SM. Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents. Journal of Clinical Oncology [Internet]. American Society of Clinical Oncology (ASCO); 2006 Apr;24(10):1633–42. Available from: https://doi.org/10.1200/jco.2005.04.0543
Grant SC, Kris MG. New antineoplastic agents in lung cancer 1988–1993. Lung Cancer [Internet]. Springer US; 1994;323–47. Available from: https://doi.org/10.1007/978-1-4615-2630-8_15
Rowinsky EK, Donehower RC. Paclitaxel (Taxol). Wood AJJ, editor. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 1995 Apr 13;332(15):1004–14. Available from: https://doi.org/10.1056/nejm199504133321507
Bagby GC. Leukopenia and leukocytosis. Cecil Textbook of Medicine 22nd edition. Goldman L, Ausiello D eds. Saunders, Philadelphia; 2007. 90-98.
Ashariati A. Komplikasi neoplasia dan terapi. Naskah lengkap Surabaya Hematologi Onkologi Medik Update-IV. Editor Boediwarsono, Sugianto, Ashariati A, Sedana MP, Ugroseno. Surabaya September 2nd. 2006; 59-67.
Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, et al. Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group. Cancer Investigation [Internet]. Informa UK Limited; 1992 Jan;10(1):1–9. Available from: https://doi.org/10.3109/07357909209032783
Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, Osuga T, Hirakawa M, Miyanishi K, Sagawa T, Fujikawa K, Ohi M, Okagawa Y, Tsuji Y, Hirayama M, Ito T, Nobuoka T, Takemasa I, Kobune M, Kato J. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study. Cancer Sci. 2018; 109(11):3554-3563.
Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, et al. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study. Cancer Science [Internet]. Wiley; 2018 Sep 25;109(11):3554–63. Available from: https://doi.org/10.1111/cas.13772
Peretz T, Sulkes A, Chollet P, Gelmon K, Paridaens R, Gorbonuva V, et al. 345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). European Journal of Cancer [Internet]. Elsevier BV; 1995 Nov;31:S75. Available from: https://doi.org/10.1016/0959-8049(95)95598-z
Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations.2nd ed. Elsevier. Philadelphia, 2005. 25-37.
This work is licensed under a Creative Commons Attribution 4.0 International License